NEW YORK--(BUSINESS WIRE)--TONIX Pharmaceuticals Holding Corp. (OTCBB:TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), has received net proceeds of approximately $1.9 million in a private placement offering to institutional and accredited investors (the “Offering”). In addition, $1.9 million of previously issued convertible debentures converted into the Offering.
